JP2009515836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515836A5 JP2009515836A5 JP2008539089A JP2008539089A JP2009515836A5 JP 2009515836 A5 JP2009515836 A5 JP 2009515836A5 JP 2008539089 A JP2008539089 A JP 2008539089A JP 2008539089 A JP2008539089 A JP 2008539089A JP 2009515836 A5 JP2009515836 A5 JP 2009515836A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- formula
- composition
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 96
- 238000000034 method Methods 0.000 claims 35
- 239000000203 mixture Substances 0.000 claims 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 26
- 239000007787 solid Substances 0.000 claims 26
- 239000002904 solvent Substances 0.000 claims 24
- 239000003814 drug Substances 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 238000002329 infrared spectrum Methods 0.000 claims 14
- 229940124597 therapeutic agent Drugs 0.000 claims 14
- -1 6-Fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl Chemical group 0.000 claims 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 12
- 206010002388 Angina unstable Diseases 0.000 claims 11
- 208000007814 Unstable Angina Diseases 0.000 claims 11
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- 241000124008 Mammalia Species 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 9
- 206010000891 acute myocardial infarction Diseases 0.000 claims 9
- 239000013078 crystal Substances 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 230000000302 ischemic effect Effects 0.000 claims 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 8
- 239000003146 anticoagulant agent Substances 0.000 claims 8
- 210000004351 coronary vessel Anatomy 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 238000001356 surgical procedure Methods 0.000 claims 8
- 208000007718 Stable Angina Diseases 0.000 claims 7
- 208000006011 Stroke Diseases 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 7
- 238000002399 angioplasty Methods 0.000 claims 7
- 238000013172 carotid endarterectomy Methods 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 238000001035 drying Methods 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 6
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 5
- 208000005189 Embolism Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229940100389 Sulfonylurea Drugs 0.000 claims 5
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 5
- 206010047249 Venous thrombosis Diseases 0.000 claims 5
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 201000011461 pre-eclampsia Diseases 0.000 claims 5
- 201000005665 thrombophilia Diseases 0.000 claims 5
- 230000001732 thrombotic effect Effects 0.000 claims 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 230000000702 anti-platelet effect Effects 0.000 claims 4
- 229940127219 anticoagulant drug Drugs 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 238000007887 coronary angioplasty Methods 0.000 claims 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 4
- YPHXEBPBOGJRII-UHFFFAOYSA-N potassium;sulfonylurea Chemical compound [K].NC(=O)N=S(=O)=O YPHXEBPBOGJRII-UHFFFAOYSA-N 0.000 claims 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 4
- 238000007631 vascular surgery Methods 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 208000029078 coronary artery disease Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 230000001052 transient effect Effects 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- WUPZRLYEGIXBNO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea Chemical compound O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 WUPZRLYEGIXBNO-UHFFFAOYSA-N 0.000 claims 2
- QHFUNOSLYOQGKO-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea;potassium Chemical compound [K].O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 QHFUNOSLYOQGKO-UHFFFAOYSA-N 0.000 claims 2
- HQKSVTNOXNXOGZ-UHFFFAOYSA-N 1-(5-chlorothiophen-2-yl)sulfonyl-1-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1h-quinazolin-3-yl]phenyl]urea;sodium Chemical compound [Na].O=C1C=2C=C(F)C(NC)=CC=2NC(=O)N1C(C=C1)=CC=C1N(C(N)=O)S(=O)(=O)C1=CC=C(Cl)S1 HQKSVTNOXNXOGZ-UHFFFAOYSA-N 0.000 claims 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims 2
- 239000000006 Nitroglycerin Substances 0.000 claims 2
- 206010038563 Reocclusion Diseases 0.000 claims 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 2
- 206010043647 Thrombotic Stroke Diseases 0.000 claims 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 2
- 230000010933 acylation Effects 0.000 claims 2
- 238000005917 acylation reaction Methods 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 229940127226 anticholesterol agent Drugs 0.000 claims 2
- 239000003420 antiserotonin agent Substances 0.000 claims 2
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229940072645 coumadin Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 229960003711 glyceryl trinitrate Drugs 0.000 claims 2
- 229960002897 heparin Drugs 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 229940118179 lovenox Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 150000003246 quinazolines Chemical class 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- BBZGPVLOWDIXCM-UHFFFAOYSA-N sodium;sulfonylurea Chemical compound [Na].NC(=O)N=S(=O)=O BBZGPVLOWDIXCM-UHFFFAOYSA-N 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 2
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 claims 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 claims 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 claims 1
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims 1
- 102000003938 Thromboxane Receptors Human genes 0.000 claims 1
- 108090000300 Thromboxane Receptors Proteins 0.000 claims 1
- WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000002473 artificial blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007971 neurological deficit Effects 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims 1
- 0 CC=[S@](c([s]1)ccc1Cl)NC(Nc(cc1)ccc1N(C(c1cc(*)c(*)cc1N1)=O)C1=O)=O Chemical compound CC=[S@](c([s]1)ccc1Cl)NC(Nc(cc1)ccc1N(C(c1cc(*)c(*)cc1N1)=O)C1=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73365005P | 2005-11-03 | 2005-11-03 | |
| US60/733,650 | 2005-11-03 | ||
| PCT/US2006/043093 WO2007056219A2 (en) | 2005-11-03 | 2006-11-03 | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515836A JP2009515836A (ja) | 2009-04-16 |
| JP2009515836A5 true JP2009515836A5 (https=) | 2010-12-09 |
| JP5509406B2 JP5509406B2 (ja) | 2014-06-04 |
Family
ID=38023842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539089A Active JP5509406B2 (ja) | 2005-11-03 | 2006-11-03 | ［４−（６−ハロ−７−置換−２，４−ジオキソ−１，４−ジヒドロ−２ｈ−キナゾリン−３−イル）−フェニル］−５−クロロ−チオフェン−２−イル−スルホニル尿素、ならびにそれに関連する形態および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US8058284B2 (https=) |
| EP (2) | EP1951254B1 (https=) |
| JP (1) | JP5509406B2 (https=) |
| KR (1) | KR101423483B1 (https=) |
| CN (1) | CN101300013B (https=) |
| AR (1) | AR056762A1 (https=) |
| AT (1) | ATE540034T1 (https=) |
| AU (1) | AU2006311795B2 (https=) |
| BR (1) | BRPI0618210A2 (https=) |
| CA (1) | CA2627719C (https=) |
| CY (1) | CY1112826T1 (https=) |
| DK (1) | DK1951254T3 (https=) |
| EA (1) | EA017402B1 (https=) |
| ES (1) | ES2380814T3 (https=) |
| IL (1) | IL191193A (https=) |
| NZ (2) | NZ596025A (https=) |
| PT (1) | PT1951254E (https=) |
| TW (2) | TWI397529B (https=) |
| WO (2) | WO2007056219A2 (https=) |
| ZA (1) | ZA200804241B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101195801B1 (ko) | 2004-06-18 | 2012-11-05 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자 억제제 |
| KR101423483B1 (ko) | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| MX2008014193A (es) | 2006-05-05 | 2009-03-31 | Millennium Pharm Inc | Inhibidores del factor xa. |
| TW200911755A (en) | 2007-04-19 | 2009-03-16 | Astellas Pharma Inc | Bicyclic heterocyclic compounds |
| MX2009011755A (es) * | 2007-05-02 | 2010-02-12 | Portola Pharm Inc | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. |
| US20090048216A1 (en) | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| BRPI0810800A2 (pt) * | 2007-05-02 | 2014-10-29 | Portola Pharm Inc | Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles. |
| CN101679358B (zh) * | 2007-06-18 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 作为p2y12拮抗剂的吡咯衍生物 |
| CN101654441B (zh) * | 2008-08-19 | 2012-10-03 | 信谊药厂 | 抗凝化合物、组合物及其用途 |
| EP2376065A2 (en) * | 2008-11-14 | 2011-10-19 | Portola Pharmaceuticals, Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof |
| WO2011006169A1 (en) | 2009-07-10 | 2011-01-13 | Portola Pharmaceuticals, Inc. | Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
| ES2470329T3 (es) | 2009-08-28 | 2014-06-23 | Daiichi Sankyo Company, Limited | Derivado del ácido 3-(biariloxi) priopi�nico |
| CA2784921A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
| US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
| US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
| WO2014042176A1 (ja) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| RU2556198C1 (ru) * | 2014-04-10 | 2015-07-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ профилактики развития постперикардиотомного синдрома у больных ишемической болезнью сердца, подвергшихся коронарному шунтированию |
| WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE845042C (de) | 1950-07-14 | 1952-07-28 | Basf Ag | Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden |
| US3847925A (en) * | 1971-07-15 | 1974-11-12 | En Nom Collectif Science Et Ci | Benzenesulfonyl semicarbazides |
| DE3134780A1 (de) * | 1981-09-02 | 1983-03-10 | Hoechst Ag, 6000 Frankfurt | "sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung" |
| US4720450A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
| GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| US6268380B1 (en) | 1993-02-19 | 2001-07-31 | G. D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| AU6395094A (en) | 1993-03-15 | 1994-10-11 | G.D. Searle & Co. | Urea derivatives useful as platelet aggregation inhibitors |
| JPH0881442A (ja) | 1994-07-14 | 1996-03-26 | Otsuka Pharmaceut Co Ltd | 環状アミド誘導体 |
| TW448161B (en) | 1994-07-14 | 2001-08-01 | Otsuka Pharma Co Ltd | Cyclic amide derivatives |
| US6413724B1 (en) * | 1996-10-28 | 2002-07-02 | Versicor, Inc. | Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones |
| US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
| JPH10195323A (ja) | 1997-01-09 | 1998-07-28 | Nippon Paper Ind Co Ltd | 新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体 |
| SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| JP2002509152A (ja) | 1998-01-15 | 2002-03-26 | シーオーアール セラピューティクス インコーポレイテッド | 血小板ａｄｐ受容体阻害剤 |
| JP2000204081A (ja) | 1998-02-05 | 2000-07-25 | Takeda Chem Ind Ltd | スルホンアミド誘導体、その製造法及び用途 |
| DK1257550T3 (da) * | 2000-02-04 | 2006-03-27 | Portola Pharm Inc | Blodplade-ADP-receptor-inhibitor |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| DE60144284D1 (de) * | 2000-11-01 | 2011-05-05 | Millennium Pharm Inc | Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung |
| AU2003210477A1 (en) * | 2002-01-09 | 2003-07-30 | Enzrel, Inc. | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| US20040242658A1 (en) * | 2003-01-08 | 2004-12-02 | Dr. Reddy's Laboratories Limited | Amorphous form of rosiglitazone maleate and process for preparation thereof |
| AU2004278030C1 (en) * | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
| KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| BRPI0810800A2 (pt) * | 2007-05-02 | 2014-10-29 | Portola Pharm Inc | Sais de [4-(6-fluoro-7-metilamino-2,4-dioxo-1, 4-diidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-s ulfonilureia, formas e métodos relacionados a eles. |
| US20090048216A1 (en) * | 2007-05-02 | 2009-02-19 | Portola Pharmaceuticals, Inc. | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
-
2006
- 2006-11-03 KR KR1020087013178A patent/KR101423483B1/ko not_active Expired - Fee Related
- 2006-11-03 ZA ZA200804241A patent/ZA200804241B/xx unknown
- 2006-11-03 ES ES06827506T patent/ES2380814T3/es active Active
- 2006-11-03 US US11/556,490 patent/US8058284B2/en active Active
- 2006-11-03 WO PCT/US2006/043093 patent/WO2007056219A2/en not_active Ceased
- 2006-11-03 AR ARP060104840A patent/AR056762A1/es unknown
- 2006-11-03 TW TW095140753A patent/TWI397529B/zh not_active IP Right Cessation
- 2006-11-03 EP EP06827506A patent/EP1951254B1/en active Active
- 2006-11-03 AU AU2006311795A patent/AU2006311795B2/en not_active Ceased
- 2006-11-03 AT AT06827506T patent/ATE540034T1/de active
- 2006-11-03 NZ NZ596025A patent/NZ596025A/xx not_active IP Right Cessation
- 2006-11-03 EA EA200801245A patent/EA017402B1/ru not_active IP Right Cessation
- 2006-11-03 CA CA2627719A patent/CA2627719C/en not_active Expired - Fee Related
- 2006-11-03 BR BRPI0618210-0A patent/BRPI0618210A2/pt not_active Application Discontinuation
- 2006-11-03 TW TW095140749A patent/TW200728260A/zh unknown
- 2006-11-03 DK DK06827506.4T patent/DK1951254T3/da active
- 2006-11-03 JP JP2008539089A patent/JP5509406B2/ja active Active
- 2006-11-03 NZ NZ567747A patent/NZ567747A/en not_active IP Right Cessation
- 2006-11-03 CN CN2006800410635A patent/CN101300013B/zh not_active Expired - Fee Related
- 2006-11-03 PT PT06827506T patent/PT1951254E/pt unknown
- 2006-11-03 US US11/556,518 patent/US20070208045A1/en not_active Abandoned
- 2006-11-03 WO PCT/US2006/042998 patent/WO2007056167A2/en not_active Ceased
- 2006-11-03 EP EP11176014A patent/EP2428514A1/en not_active Withdrawn
-
2008
- 2008-05-01 IL IL191193A patent/IL191193A/en not_active IP Right Cessation
-
2011
- 2011-10-11 US US13/271,037 patent/US20120088736A1/en not_active Abandoned
-
2012
- 2012-04-04 CY CY20121100393T patent/CY1112826T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515836A5 (https=) | ||
| AU2020203464B2 (en) | Sulfonylureas and related compounds and use of same | |
| CA2829790C (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
| JP4657384B2 (ja) | ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体 | |
| JP3335362B2 (ja) | キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト | |
| JPH05508660A (ja) | ジアリールメチルピペリジンまたはピペラジンのピリジンおよびピリジンｎ−オキシド誘導体、並びにそれらの組成物および使用方法 | |
| PL214701B1 (pl) | Pochodna piperydyny, kompozycja farmaceutyczna zawierajaca te pochodna oraz zastosowanie lecznicze tej pochodnej | |
| TW200402294A (en) | Chemical compounds | |
| JPH02218668A (ja) | キナゾリン、その製法及び該化合物を含有する抗腫瘍作用を有する医薬組成物 | |
| EP2138482A1 (en) | Bicyclic heterocyclic compound | |
| JP2008502628A (ja) | ピリダジン−３（２ｈ）−オン誘導体およびｐｄｅ４の阻害剤としてのそれらの使用 | |
| SK61399A3 (en) | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | |
| JP2008543956A (ja) | Ｒｈｏ−キナーゼの阻害剤としてのイソキノリン誘導体 | |
| TW200803852A (en) | Inhibitors of histone deacetylase for the treatment of disease | |
| CN101652366A (zh) | 新型抗叶酸剂 | |
| TW201632504A (zh) | ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途 | |
| MXPA06003625A (es) | Isoquinolinonas sustituidas. | |
| JP2010235635A (ja) | 多酸性塩基化合物の酸付加塩の製造方法 | |
| AU7446500A (en) | Novel quinazoline derivatives | |
| JP2009542641A (ja) | 新規ピリジン類縁体 | |
| JPH0471077B2 (https=) | ||
| JP2010526105A5 (https=) | ||
| TW200413367A (en) | Novel processes and intermediates for preparing triazolo-pyridines | |
| PL183867B1 (pl) | Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny | |
| CN105008347A (zh) | 作为钾离子通道抑制剂的异喹啉类化合物 |